Federal Court Rejected AstraZeneca Motion in Arkansas
A federal judge denied AstraZeneca's request to block an Arkansas state law regulating pharmacy drug contracts.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Should states be allowed to regulate how drug manufacturers contract with pharmacies for discount programs?
The U.S. District Court for the Eastern District of Arkansas has denied a motion for summary judgment filed by AstraZeneca. The pharmaceutical company sought to block the enforcement of the Arkansas 340B Drug Pricing Nondiscrimination Act.
Why it matters
The ruling allows the Arkansas law, which prohibits drug manufacturers from restricting pharmacy participation in the 340B program, to remain in effect. This legal challenge underscores ongoing disputes regarding federal and state authority over pharmacy contract regulations.
The ruling concerns the Arkansas 340B Drug Pricing Nondiscrimination Act, which prevents manufacturers from restricting pharmacy participation in the federal 340B program. The full legal impact remains subject to further litigation in the district court.
The players
AstraZeneca
This is a multinational pharmaceutical and biotechnology company that develops and markets various prescription medicines.
U.S. District Court for the Eastern District of Arkansas
This is a federal judicial body that has jurisdiction over legal proceedings occurring within the eastern half of the state of Arkansas.
The details
AstraZeneca had filed the motion in an attempt to invalidate the state statute, which enforces specific requirements on drug manufacturer contracts. The court's denial of this motion means the state's regulatory framework for the 340B program will continue to be enforced as the case proceeds.
Timeline
September 29, 2026: The federal court formally denied the motion for summary judgment filed by AstraZeneca.
Market Landscape
The ruling reinforces the regulatory authority of the 340B Drug Pricing Nondiscrimination Act within the state pharmaceutical supply chain. This decision signals a continued pushback against efforts by drug manufacturers to centralize control over pharmacy contracts.
The continuation of the Arkansas law ensures that pharmacies operating within the state can maintain participation in the 340B program. This stability may protect the current availability and pricing structures for certain prescription drugs for local patients and providers.
The takeaway
The court's decision affirms the validity of state-level oversight regarding 340B program participation. Stakeholders in the healthcare supply chain should monitor future judicial proceedings for further clarity on these contract regulations.
Further reading
Learn more about the evolving landscape of Healthcare policy and state regulations.
Source note: This article includes information reported by Bloomberglaw.
Live Poll
Should states be allowed to regulate how drug manufacturers contract with pharmacies for discount programs?
